Silexion Therapeutics CORP (SLXNW) — DEF 14A Filings
All DEF 14A filings from Silexion Therapeutics CORP. Browse 2 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (2)
-
Silexion Seeks Shareholder Nod for 500%+ Capital Increase
— Jul 31, 2025 Risk: medium
Silexion Therapeutics Corp (SLXNW) is seeking shareholder approval to increase its authorized share capital from US$20,000, divided into 1,481,482 ordinary shar -
Silexion Sets July 7 Shareholder Meeting for Director, Auditor Votes
— Jun 16, 2025 Risk: low
Silexion Therapeutics Corp (SLXNW) filed a Definitive Proxy Statement (DEF 14A) on June 16, 2025, for its annual general meeting scheduled for July 7, 2025. The
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX